Delcath Sticks With Melblez Chemosaturation But Dumps CEO On FDA Rebuff
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s “complete response” letter requesting further studies is no surprise after a scathing ODAC assessment in May, but with an interim CEO team in place, the company says it’s ready to work things out with regulators.